Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase EARLY_PHASE1 1

Status

Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 1Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 4Ovarian Neoplasms 1Endometrial Neoplasms 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 485Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
onapristone × Breast × Clear all
NCT05618613 2025-05-09

ELONA

Context Therapeutics Inc.

Phase 1/2 Terminated
4 enrolled
Breast

Breast Neoplasms

NCT06938711 2025-04-22

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Context Therapeutics Inc.

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

NCT04142892 2022-04-01

ONAWA

SOLTI Breast Cancer Research Group

Phase EARLY_PHASE1 Completed
10 enrolled
Breast

Breast Neoplasms

NCT02052128 2015-06-24

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

Arno Therapeutics

Phase 1/2 Unknown
60 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡